Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
about
CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinomaA Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies.Cutting Edge: Elevated Leptin during Diet-Induced Obesity Reduces the Efficacy of Tumor ImmunotherapyLarge-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity
P2860
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
@ast
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
@en
type
label
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
@ast
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
@en
prefLabel
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
@ast
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
@en
P2093
P2860
P1476
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
@en
P2093
Britnie R James
Erik L Brincks
Louis Boon
Tamara A Kucaba
Thomas S Griffith
P2860
P2888
P304
P356
10.1007/S00262-014-1548-5
P577
2014-04-08T00:00:00Z
P5875
P6179
1039195100